Drug intelligence / Profile preview

Dead Mesenchymal Stem Cells

Development stage: Phase 2
Modality: Cell Therapies
Administration: Infusion

Overview

Dead Mesenchymal Stem Cells (hDMSCs) are a cell therapy under investigation for the treatment of radiation lung injury. This therapy is being explored in a single-center, single-arm, prospective clinical trial to assess its safety and efficacy. The study involves a dose-climbing design, with an initial dose determined from preclinical research in mice. The treatment regimen includes multiple infusions over several weeks.

Other names: death mesenchymal stem cell

Beyond the preview

Go deeper on Dead Mesenchymal Stem Cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dead Mesenchymal Stem Cells.

Explore the full profile